179 related articles for article (PubMed ID: 32700091)
1. Identification of STXBP6-IRF1 positive feedback loop in regulation of PD-L1 in cancer.
Liu Y; Huang Z; Wei Y; Zhang M; Li X; Yang S; Wang H
Cancer Immunol Immunother; 2021 Feb; 70(2):275-287. PubMed ID: 32700091
[TBL] [Abstract][Full Text] [Related]
2. SPOP mutations promote tumor immune escape in endometrial cancer via the IRF1-PD-L1 axis.
Gao K; Shi Q; Gu Y; Yang W; He Y; Lv Z; Ding Y; Cao W; Wang C; Wan X
Cell Death Differ; 2023 Feb; 30(2):475-487. PubMed ID: 36481790
[TBL] [Abstract][Full Text] [Related]
3. KPNB1 Inhibitor Importazole Reduces Ionizing Radiation-Increased Cell Surface PD-L1 Expression by Modulating Expression and Nuclear Import of IRF1.
Yoshino H; Sato Y; Nakano M
Curr Issues Mol Biol; 2021 May; 43(1):153-162. PubMed ID: 34069326
[TBL] [Abstract][Full Text] [Related]
4. Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.
Garcia-Diaz A; Shin DS; Moreno BH; Saco J; Escuin-Ordinas H; Rodriguez GA; Zaretsky JM; Sun L; Hugo W; Wang X; Parisi G; Saus CP; Torrejon DY; Graeber TG; Comin-Anduix B; Hu-Lieskovan S; Damoiseaux R; Lo RS; Ribas A
Cell Rep; 2017 May; 19(6):1189-1201. PubMed ID: 28494868
[TBL] [Abstract][Full Text] [Related]
5. Interplay between interferon regulatory factor 1 and BRD4 in the regulation of PD-L1 in pancreatic stellate cells.
Ebine K; Kumar K; Pham TN; Shields MA; Collier KA; Shang M; DeCant BT; Urrutia R; Hwang RF; Grimaldo S; Principe DR; Grippo PJ; Bentrem DJ; Munshi HG
Sci Rep; 2018 Sep; 8(1):13225. PubMed ID: 30185888
[TBL] [Abstract][Full Text] [Related]
6. IFNγ-induced PD-L1 expression in ovarian cancer cells is regulated by JAK1, STAT1 and IRF1 signaling.
Padmanabhan S; Gaire B; Zou Y; Uddin MM; Vancurova I
Cell Signal; 2022 Sep; 97():110400. PubMed ID: 35820543
[TBL] [Abstract][Full Text] [Related]
7. Triptolide reduces PD-L1 through the EGFR and IFN-γ/IRF1 dual signaling pathways.
Xie Y; Ding J; Gao J; Zhang J; Cen S; Zhou J
Int Immunopharmacol; 2023 May; 118():109993. PubMed ID: 36931170
[TBL] [Abstract][Full Text] [Related]
8. Disrupting the phase separation of KAT8-IRF1 diminishes PD-L1 expression and promotes antitumor immunity.
Wu Y; Zhou L; Zou Y; Zhang Y; Zhang M; Xu L; Zheng L; He W; Yu K; Li T; Zhang X; Chen Z; Zhang R; Zhou P; Zhang N; Zheng L; Kang T
Nat Cancer; 2023 Mar; 4(3):382-400. PubMed ID: 36894639
[TBL] [Abstract][Full Text] [Related]
9. Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells.
Yan Y; Zheng L; Du Q; Yan B; Geller DA
Cancer Immunol Immunother; 2020 Sep; 69(9):1891-1903. PubMed ID: 32377817
[TBL] [Abstract][Full Text] [Related]
10. Verteporfin Inhibits PD-L1 through Autophagy and the STAT1-IRF1-TRIM28 Signaling Axis, Exerting Antitumor Efficacy.
Liang J; Wang L; Wang C; Shen J; Su B; Marisetty AL; Fang D; Kassab C; Jeong KJ; Zhao W; Lu Y; Jain AK; Zhou Z; Liang H; Sun SC; Lu C; Xu ZX; Yu Q; Shao S; Chen X; Gao M; Claret FX; Ding Z; Chen J; Chen P; Barton MC; Peng G; Mills GB; Heimberger AB
Cancer Immunol Res; 2020 Jul; 8(7):952-965. PubMed ID: 32265228
[TBL] [Abstract][Full Text] [Related]
11. IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell.
Shao L; Hou W; Scharping NE; Vendetti FP; Srivastava R; Roy CN; Menk AV; Wang Y; Chauvin JM; Karukonda P; Thorne SH; Hornung V; Zarour HM; Bakkenist CJ; Delgoffe GM; Sarkar SN
Cancer Immunol Res; 2019 Aug; 7(8):1258-1266. PubMed ID: 31239318
[TBL] [Abstract][Full Text] [Related]
12. SOX10 Regulates Melanoma Immunogenicity through an IRF4-IRF1 Axis.
Yokoyama S; Takahashi A; Kikuchi R; Nishibu S; Lo JA; Hejna M; Moon WM; Kato S; Zhou Y; Hodi FS; Song JS; Sakurai H; Fisher DE; Hayakawa Y
Cancer Res; 2021 Dec; 81(24):6131-6141. PubMed ID: 34728538
[TBL] [Abstract][Full Text] [Related]
13. Demethylase JMJD2D induces PD-L1 expression to promote colorectal cancer immune escape by enhancing IFNGR1-STAT3-IRF1 signaling.
Chen Q; Zhuang S; Hong Y; Yang L; Guo P; Mo P; Peng K; Li W; Xiao N; Yu C
Oncogene; 2022 Mar; 41(10):1421-1433. PubMed ID: 35027670
[TBL] [Abstract][Full Text] [Related]
14. IFN-γ-mediated IRF1/miR-29b feedback loop suppresses colorectal cancer cell growth and metastasis by repressing IGF1.
Yuan L; Zhou C; Lu Y; Hong M; Zhang Z; Zhang Z; Chang Y; Zhang C; Li X
Cancer Lett; 2015 Apr; 359(1):136-47. PubMed ID: 25592039
[TBL] [Abstract][Full Text] [Related]
15. UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced
Wu B; Song M; Dong Q; Xiang G; Li J; Ma X; Wei F
Theranostics; 2022; 12(11):5086-5102. PubMed ID: 35836797
[No Abstract] [Full Text] [Related]
16. EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma.
Xiao G; Jin LL; Liu CQ; Wang YC; Meng YM; Zhou ZG; Chen J; Yu XJ; Zhang YJ; Xu J; Zheng L
J Immunother Cancer; 2019 Nov; 7(1):300. PubMed ID: 31727135
[TBL] [Abstract][Full Text] [Related]
17. Myricetin inhibits interferon-γ-induced PD-L1 and IDO1 expression in lung cancer cells.
Chen YC; He XL; Qi L; Shi W; Yuan LW; Huang MY; Xu YL; Chen X; Gu L; Zhang LL; Lu JJ
Biochem Pharmacol; 2022 Mar; 197():114940. PubMed ID: 35120895
[TBL] [Abstract][Full Text] [Related]
18. IFNAR1 Controls Autocrine Type I IFN Regulation of PD-L1 Expression in Myeloid-Derived Suppressor Cells.
Xiao W; Klement JD; Lu C; Ibrahim ML; Liu K
J Immunol; 2018 Jul; 201(1):264-277. PubMed ID: 29752314
[TBL] [Abstract][Full Text] [Related]
19. CRISPR screening identifies the deubiquitylase ATXN3 as a PD-L1-positive regulator for tumor immune evasion.
Wang S; Iyer R; Han X; Wei J; Li N; Cheng Y; Zhou Y; Gao Q; Zhang L; Yan M; Sun Z; Fang D
J Clin Invest; 2023 Dec; 133(23):. PubMed ID: 38038129
[TBL] [Abstract][Full Text] [Related]
20. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
